Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies

Author(s): Michele Moschetta, Marta Cesca, Francesca Pretto and Raffaella Giavazzi

Volume 16, Issue 35, 2010

Page: [3921 - 3931] Pages: 11

DOI: 10.2174/138161210794455021

Price: $65


Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.

Keywords: Angiogenesis, VEGF, Combination Therapy, Biomarker, Resistance, Toxicity, bevacizumab, Avastin, TKRI, sunitinib, GIST, pazopanib, EGFR, PDGFR, FGFR, CRC, NSCLC, ABT-869, Axitinib, BIBF1120, Brivanib, Cediranib, Dovitinib, Foretinib, Motesanib, Sorafenib, Vandetanib, Vatalanib, ZD6474, carboplatin, paclitaxel, trastuzumab, Radio-Immunotherapy, Tregs, TKRI therapy, PlGF, hypothyroidism, neuropathy

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy